CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"Novartis secures new radioligand in $900M deal as competition strengthens","$":{"href":"/biotech/novartis-secures-new-radioligand-900m-deal-competition-strengthens","hreflang":"en"}}]}

PartnershipRadioligand therapyPositive
AI Analysis

Summary

Novartis has licensed a preclinical radioligand therapy from a Chinese biotech in a $900M deal to strengthen its radiopharmaceutical pipeline amid increasing competition in the sector.

Importance:7/10
Sentiment:
0.60
radioligand therapyradiopharmaceuticalslicensing dealpipeline expansiononcology
Related Companies

Read the original article

Published by FierceBiotech on September 22, 2026 1:26 PM

Read Original